Auszug
Das maligne Melanom ist der häufigste Hauttumor. Die immer noch jährlich um etwa 7 % steigende Inzidenz und eine Mortalitätsrate von 20–25 % haben diesen Tumor in den Mittelpunkt aller therapeutischen Bemühungen in der Dermato-Onkologie gestellt. In Deutschland ist von einer Erkrankungsrate von 11 je 100 000 Einwohner pro Jahr auszugehen. Das entspricht damit auch der Inzidenz von 0,012 % in Österreich.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Avril MF, Aamdal S, Grob JJ, Hauschild A, Mohr P, Bonerandi JJ, Weichenthal M, Neuber K, Bieber T, Gilde K, Guillem Porta V, Fra J, Bonneterre J, SaïKamanabrou D, Pehamberger H, Sufliarsky J, Gonzalez Larriba JL, Scherrer A, Menu Y. (2004) Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol 22(6): 1118–1125
Balch CM, Urist MM, Karakouis CP, Smith TJ, Temple WJ, Drzewiecki K, Jewell WR, Bartolucci AA, Mihm CM, Barnhill R, Wanebo HJ (1993) Efficacy of 2-cm Surgical margins for intermediate thickness melanomas (1 to 4 mm). Ann Surg 218: 262–269
Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton A Jr, Kirkwood JM, McMasters KM, Mihm MF, Morton DL, Reintgen DS, Ross MI, Sober A, Thompson JA, Thompson JF (2001) Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19: 3635–3648
Balch CM, Soong SJ, Gerschenwald JE, Thompson JF, Reintgen DS, Cascinelli N et al (2001) Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 19: 3822–3834
Breslow A, Macht SD (1977) Optimal size of resection margin for thin cutaneous melanoma. Surg Gynecol Obstet 145: 691–692
Creech O, Krementz ET, Ryan RF et al. (1958) Chemotherapy of cancer: regional perfusion utilizing an extracorporal cicuit. Ann Surg. 148: 616–631
Dadras SS, Lange-Asschenfeldt B, Velasco P, Nguyen L, Vora A, Muzikansky A, Jahnke K, Hauschild A, Hirakawa S, Mihm MC, Detmar M (2005) Tumor lymphangiogenesis predicts melanoma metastasis to sentinel lymph nodes. Mod Pathol 2005 18: 1232–1426
Eggermont AM und ten Hagen TL (2003) Regionale Tumortherapie. Springer Berlin Heidelberg: 159–171
Eigentler TK, Caroli UM, Radny P, Garbe C (2003) Palliative therapy of disseminated malignant melanoma: a systemic review of 41 randomised clinical trials. Lancet Oncol 4: 48–59
Garbe C, Schadendorf D (2003) Surveillance and follow-up examinations in cutaneous melanoma. Onkologie 26: 241–246
Gershenwald JE, Thompson W, Mansfield PF, Lee JE, Colome MI, Tseng CH, Lee JJ, Balch CM, Reintgen DS, Ross MI (1999) Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymphe node status in 612 stage I or II melanoma patients. J Clin Oncol 17: 976–983
Handley WS (1907) The pathology of melanotic growths in relation to their operative treatment. Lancet 1: 927–935
Hauschild A, Christophers E (2001) Sentinel node biopsy in melanoma. Virchows Arch 438: 99–106
Hauschild A, Rosien F, Lischner S (2003) Surgical standards in the primary care of melanoma patients. Onkologie 26: 218–222
Kaufmann R (1997) Operative Therapie des primären Melanoms. In: Garbe C, Dummer R, Kaufmann R, Tilgen W Dermatologische Onkologie, Springer, Berlin Heidelberg New York, pp 330–33515.
Knorr C, Meyer T, Janssen T et al (2006) Hyperthermic isolated limb perfusion (HILP) in malignant melanoma. Experience in 101 patients. Eur J Surg Oncol 32: 224–227
Lederman JS, Lederman MD, Sober AJ (1985) Does biopsy type influence survival in clinical Stage I cutaneous melanoma? J Am Acad Dermatol 13: 983–98718
Lens MB, Dawes M, Newton-Bishop JA, Goodacre T (2002) Tumour thickness as a predictor of occult lymph node metastases in patients with stage I and II melanoma undergoing sentinel lymph node biopsy. Br J Surg 89(10): 1223–1227
Leyvraz S, Spataro V, Bauer J et al. (1997) Treatment of ocular melanoma metastatic to the liver by hepatic arterial chemotherapy. J Clin Oncol 15: 2589–2595
Macripòglino P, Caliendo V, Ronco AM, Soltani S, Giacone E, Pau S, Fierro MT, Bernengo MG (2004) Sentinel lymph node dissection in stage I/II melanoma patients: surgical management and clinical follow-up study. Melanoma Res 14(2): S9–S12
Meier F, Will S, Ellwanger U, Schlagenhauff B, Schittek B, Rassner G, Garbe C (2002) Metastatic pathways and time courses in the orderly progression of cutaneous melanoma. Br J Dermatol 147: 62–70
Möhrle M, Schippert W, Garbe C, Rassner M, Röcken M, Breuninger H (2003) Prognostische Faktoren und operative Strategien bei Melanomen des Gesichts. JDDG 1: 457–463
Möhrle M, Breuninger H (2005) Sentinel-Node-Biopsie. Welche Aussagen sind gesichert? Hautarzt 56: 441–447
Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Eleshoff R, Essner R et al. (2006) Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 355: 1307–1317
Morton DL, Wen DR, Wong JH, Economou JS, Cagle LA, Storm FK, Foshag LJ, Cochran AJ (1992) Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 127(4): 392–399
Ollila DW (2006) Complete metastasectomy in patients with stage IV metastatic melanoma. Lancet Oncol 7: 919–924
Ringborg U, Andersson R, Eldh J, Glaumann B, Hafström L, Jacobsson S, Jönsson P-E, Johansson H, Krysander L, Lagerlöf B. Swedish Melanoma Study Group (1996) Resection margins of 2 versus 5 cm for cutaneous malignant melanoma with a tumor thickness of 0.8 to 2.0 mm. Cancer 77: 1809–181426
Schlag PM, Stein U (Hrsg) (2007) Regional Cancer Therapy. Totowa, NJ Humana Press Inc. 455 S.
Siegel R, Hauschild A, Kettelhack C et al. (2007) Hepatic arterial Fotemustine chemotherapy in patients with liver metastases from cutaneous melanoma is as effective as in ocular melanoma. Eur J Surg Oncol 33(5): 627–632
Thomas JM, Newton-Bishop J, A’Hern R, Coombes G, Timmons M, Evans J, Cook M, Theaker J, Fallowfield M, O’Neill T, Ruka W, Bliss JM; United Kingdom Melanoma Study Group; British Association of Plastic Surgeons; Scottish Cancer Therapy Network (2004) Excision margins in high-risk malignant melanoma. N Engl J Med 350: 757–76630
Thompson JF und deWilt JH (2001) Isolated limb perfusion in the management of patients with recurrent limb melanoma: an important but limited role. Ann Surg Oncol 8: 564–565
Veronesi U, Cascinelli N, Adamus J, Balch C, Bandiera D, Barchuk A, Bufalino R, Craig P, Marsillac J de, Durand JC, Geel AM van, Holmstrom H, Hunter JA, Jorgensen OG, Kiss B, Kroon B, Lacour J, Lejeune F, MacKie R, Mechl Z, Mitrov G, Morabito A, Nosek H, Panizzon R, Prade M, Santi P, Slooten E van, Tomin R, Trapeznikov N, Tsanov T, Urist M, Wozniak KD (1988) Thin stage I primary cutaneous malignant melanoma — Comparison of excision with margins of 1 or 3 cm. N Engl J Med 318: 1159–1162
Veronesi U, Cascinelli N (1991) Narrow Excision (1-cm Margin) A safe procedure for thin cutaneous melanoma. Arch Surg 126: 438–441
Wheatley K, Ives N, Hancock B, Gore M, Eggermont A, Suciu S (2003) Does adjuvant interferon-alpha for highrisk melanoma provide a worthwile benefit? A metaanalysis of the randomised trials. Cancer Treat Rev 29: 241–252
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer-Verlag/Wien
About this chapter
Cite this chapter
Hauschild, A., Kähler, K.C., Egberts, F., Pehamberger, H., Schlag, P.M. (2008). Malignes Melanom. In: Gnant, M., Schlag, P.M. (eds) Chirurgische Onkologie. Springer, Vienna. https://doi.org/10.1007/978-3-211-48613-9_40
Download citation
DOI: https://doi.org/10.1007/978-3-211-48613-9_40
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-48612-2
Online ISBN: 978-3-211-48613-9
eBook Packages: Medicine (German Language)